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Migraine affects eight percent of children, and may require pharmacological therapy to control symptoms.  Current acute treatments include (5-Hydroxytryptamine Receptor 1 (5-HT1) receptor agonists, although the only licensed medication for paediatric patients in this class in the UK is intranasal sumatriptan. Oro-dispersible wafers of zolmitriptan are used in practice but have not been evaluated in the paediatric setting. 
Methods
A prospective case note audit of oro-dispersible zolmitriptan wafers use in the treatment of paediatric migraine by a consultant paediatric neurologist was carried out.
Results
Symptomatic benefit was noted in 71.4% (n=10) of patients who have been prescribed the oro-dispersible wafer formulation. All subgroups of migraine included in the audit had some participants who benefitted from the medication. Five patients (35.7%) complained of mild adverse effects: nausea (n=2, 14.3%); Somnolence (n=2, 14.3%); Tingling sensation on the tongue (n=1, 7.1%).  No patients had any severe adverse effects.
Conclusion




Headache is a very common symptom in children, with a prevalence of up to 58% [], with subtypes including migraine, tension and cluster headaches.  Migraine in adults and older children has three major symptom clusters: unilateral pulsating headaches with nausea and vomiting, phonophobia and photophobia; bilateral headaches, (from dull to stabbing) associated with nausea, vomiting, blurred vision, diplopia and visual symptoms; bilateral headaches (pulsating or pressing) with nausea and vomiting but few other symptoms []. However migraine may present differently in paediatric patients, especially younger children, which can make diagnosis difficult.  Alternative presentations include cyclical vomiting, abdominal migraine and benign paroxysmal vertigo of childhood [].  Overall, migraine affects approximately eight percent of children [], has a negative effect on social activity and school attendance, and adversely affects quality of life scores in a similar manner to disorders such as rheumatological disease and malignancy [, ].
Management of paediatric migraine includes non-pharmacological as well as pharmacological approaches, individually tailored to the patient and family [].  Non-pharmacological measures include identification and exclusion (or reduction) of triggering or exacerbating factors (including caffeine, reduced hydration, poor sleeping habits and stress).  Pharmacological management includes simple analgesics, anti-emetics, and specific anti-migraine analgesia (5-hydroxytryptamine receptor 1 (5-HT1) agonists e.g. sumatriptan, zolmitriptan) and prophylaxis (propranolol, topiramate or pizotifen) [].   
5-HT1 receptor agonists, have been shown to be safe and effective in the treatment of adult and paediatric migraine [].  Sumatriptan nasal spray, the only 5-HT1 receptor agonist currently licensed for use in children in the UK (age ≥12 years), and as such is recommended in NICE guidelines [].  However, there are tolerability concerns, with bad taste (25.7%), nausea (7.9%) and vomiting (3.9%) noted [].  Zolmitriptan is not currently licensed in the UK for treatment of childhood migraine [\o "Leschziner, 2006 #4"][], although studies have shown oral and intranasal formulations to be effective in this population  ADDIN EN.CITE [].  Zolmitriptan is also available as oro-dispersible wafers, which dissolve on the tongue and can be taken without water.  In principle, oro-dispersible formulation has advantages including removing the requirement for swallowing a tablet, and faster absorption via pre-gastric mucosa (avoiding first pass metabolism and increasing bioavailability) [, ].  This formulation has been shown to be effective in the acute management of migraine in adults [], and has been shown to be tolerable in both older adolescent and adult populations [], and the recent NICE guidelines suggest it may be an alternative if other treatments fail [].  However, there are no published data currently on efficacy or tolerability of zolmitriptan oro-dispersible wafers in paediatric patients.  Use of zolmitriptan oro-dispersible in our institution was formally approved by the trust clinical development evaluation group (CDEG), and is part of routine practice for patients under the care of a paediatric neurologist with migraine who are unresponsive or intolerant to other therapies. We have prospectively audited the use of this oro-dispersible wafer formulation of zolmitriptan in a tertiary paediatric migraine clinic setting.

Methods
Prospective audit of paediatric patients diagnosed with migraine by a paediatric neurologist, aged <18 years, prescribed zolmitriptan oro-dispersible wafers (2.5mg dose, with a second dose after 2 hours if 1st dose not effective), and attending a tertiary migraine clinic between 2009 and 2011, was undertaken. Ethical approval was not sought as this was an audit of current practice. Data were collected from patient case notes and clinic letters and verified by a second author.

Results
Sixteen patients were identified, although one patient was aged >18 years, and one patient had insufficient details recorded in the casenotes, therefore 14 eligible patients were included (Male = 7). Age of patients prescribed oro-dispersible zolmitriptan ranged from 8.5 to 15.6 years, with a range of migraine subtypes. Full patient demographics are summarised in table 1.
Prophylactic migraine medication was used by 35.7% (n=5) either prior to, or concurrently with, zolmitriptan, including pizotifen (n=2), topiramate (n=3), flunarizine (n=1) and propranolol (n=1) (2 patients used 2 different prophylactic medications). Acute pain relief was used by 100% (n=14) prior to and concurrently with zolmitriptan.  Patients used ibuprofen (n=8), paracetamol (n=9), codeine (n=2), and sumatriptan (n=4). 

	Mean	N	%
Age (years)MalesFemales	12.312.112.4	14Range 8.5 – 15.6 years77	1005050
Duration of onset (years)	3.1 	Range 1 – 9 years
Frequency of attacks<1/month1-4/month>4/monthDaily headache	----	0815	057736
Migraine Subtype	IHS category		
Migraine with auraMigraine without auraChronic migraineCyclical vomiting	1.21.11.5.11.3.1	6431	4329207
Associated symptomsNauseaVomiting	--	136	9343
School missed due to migraine	-	10	71
Table 1 Patient demographics. IHS: International Headache Society

Symptomatic benefit from pain and associated symptoms after using zolmitriptan wafers was noted in 71.4% (n=10) patients. Benefits described include rapid relief from headache (attack eliminated within 30 minutes in some cases), relief from nausea and vomiting, reduced intensity of migraine, shortened duration of attack and elimination of post-migraine somnolence. One patient had to take a second 2.5mg zolmitriptan wafer after 2 hours due to re-occurrence of migraine. 
Patients who benefitted from the medication had the following diagnoses: Chronic migraine (n=3, 100% with this diagnosis); Migraine with aura (n=4, 80% with this diagnosis); Migraine without aura (n=2, 67% with this diagnosis); Cyclical vomiting (n=1, only patient with this migraine subtype).
The side effects reported by patients were mild and rapidly resolved. Five patients (35.7%) complained of adverse effects of zolmitriptan wafers.  One patient reported a tingling sensation on the tongue; two (14.3%) said that the taste made them feel nauseated; two (14.3%) patients noted somnolence after taking, but could not determine if this was migraine or medication related. No hypersensitivity reactions were reported. No patient discontinued the medication during the audit period.

Discussion
These results demonstrate that zolmitriptan 2.5mg oro-dispersible wafer may be beneficial in producing relief from the symptoms of migraine in a highly selected paediatric population.  To our knowledge this is the first evaluation of efficacy and tolerability of this formulation in such any paediatric population. 
Benefit was seen in 71.4% of patients, comparable to response rates observed in other studies of zolmitriptan (oral and intranasal)  ADDIN EN.CITE [, ].  Larger prospective studies, incorporating International Headache Society preferred outcomes in children and adolescents (e.g. pain free at 2 hours, sleep, time to onset of pain relief) would be needed to ascertain the relative efficacy of this preparation compared to the other preparations available (oral/intranasal). The results also demonstrate that zolmitriptan oro-dispersible wafer may be effective in the acute management of different migraine subtypes including migraine with aura, migraine without aura, cyclical vomiting and chronic migraine. 
The side effects reported by patients were mild and rapidly resolved. The main side effect reported was nausea due to bad taste which was experienced by two patients (14.3%), lower than rates of bad taste reported with intranasal sumatriptan (25.7%) and comparable with nausea associated with other 5-HT agonist use  ADDIN EN.CITE [, ]. 
Although limited by population size, we believe that this work highlights the potential benefit, and the need for further evaluation, of this formulation of zolmitriptan.  Non-oral routes of administration of medications for the acute treatment of migraine have considerable advantages given the high frequency of associated nausea and vomiting. In addition, intranasal medications have been shown to be unacceptable to children in other settings [], and so identification of alternative, effective formulations has the potential to improve outcomes in children with migraine.  In our population it appears that oro-dispersible wafers were acceptable, but more definitive work would be required to confirm this observation. 
Conclusion






What is known about this topic

	Migraines occur in children, and may require pharmacological intervention.
	The only current licensed medication in this class is not tolerated in all children.
	There is limited evidence in children regarding other members of the 5-HT1 receptor agonist class of medications, and other formulations. 

What this study adds

	Zolmitriptan oro-dispersible wafers were effective and well tolerated in a highly selected tertiary paediatric population with migraine.
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